A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells

doi:10.1038/cddis.2015.25

Paper

A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells

Published Mar 1, 2015 · B. Chu, F. Liu, L. Li

Cell Death & Disease

Q1 SJR score

66

Citations

4

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

5a, a novel 2-aryl benzimidazole derivative, effectively inhibits EGFR and HER2 activity in breast cancer cells, promoting apoptosis and suggesting potential as a new breast cancer treatment strategy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells

References

Citations